Comparison of Clinicopathological Characteristics Between Primary and Contralateral Cancers in BRCA1/2 Carriers with Metachronous Bilateral Breast Cancers
Objective To compare the clinicopathological characteristics between primary and contralateral cancers in patients with metachronous bilateral breast cancer (MBBC) who carried a BRCA1/2 germline pathogenic variant. Methods A total of 496 BRCA1/2 carriers with primary unilateral breast cancer were in...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2023-07-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.23.0211 |
| _version_ | 1827861097086976000 |
|---|---|
| author | DING Xinyun SUN Jie CHEN Jiuan YAO Lu XU Ye XIE Yuntao ZHANG Juan |
| author_facet | DING Xinyun SUN Jie CHEN Jiuan YAO Lu XU Ye XIE Yuntao ZHANG Juan |
| author_sort | DING Xinyun |
| collection | DOAJ |
| description | Objective To compare the clinicopathological characteristics between primary and contralateral cancers in patients with metachronous bilateral breast cancer (MBBC) who carried a BRCA1/2 germline pathogenic variant. Methods A total of 496 BRCA1/2 carriers with primary unilateral breast cancer were included (196 with BRCA1 and 300 with BRCA2). Clinicopathological information of patients was collected, and the median follow-up for the entire cohort was 10.4 years (0.4-20.8 years). Results Among all patients, 31 (15.8%) of the 196 BRCA1 carriers and 49 (16.3%) of the 300 BRCA2 carriers had MBBC, respectively. Among the 31 BRCA1 carriers who developed MBBC, the proportion of triple-negative breast cancer (TNBC) in primary cancer and contralateral cancer was 61.3% and 67.7%, respectively. If the primary cancer of BRCA1-mutated MBBC was TNBC, the probability of the contralateral breast cancer with TNBC was 89.5% (17/19), which was significantly higher than that if the primary cancer was non-TNBC (33.3%, 4/12) (P=0.004). Among the 49 BRCA2 carriers who developed MBBC, the predominant molecular phenotype of the primary and contralateral cancers was HR+ & HER2- (77.6% and 67.3%, respectively; P=0.53). Conclusion Approximately 60% of BRCA1 carriers exhibit TNBC. If a BRCA1 carrier with a TNBC primary breast cancer had an MBBC, the probability of the contralateral breast cancer being TNBC phenotype is almost 89.5%. |
| first_indexed | 2024-03-12T13:32:12Z |
| format | Article |
| id | doaj.art-3a95e8d30d454b6b8cfa99e400fbe7aa |
| institution | Directory Open Access Journal |
| issn | 1000-8578 |
| language | zho |
| last_indexed | 2024-03-12T13:32:12Z |
| publishDate | 2023-07-01 |
| publisher | Magazine House of Cancer Research on Prevention and Treatment |
| record_format | Article |
| series | Zhongliu Fangzhi Yanjiu |
| spelling | doaj.art-3a95e8d30d454b6b8cfa99e400fbe7aa2023-08-24T06:55:31ZzhoMagazine House of Cancer Research on Prevention and TreatmentZhongliu Fangzhi Yanjiu1000-85782023-07-0150765265710.3971/j.issn.1000-8578.2023.23.02118578.2023.23.0211Comparison of Clinicopathological Characteristics Between Primary and Contralateral Cancers in BRCA1/2 Carriers with Metachronous Bilateral Breast CancersDING Xinyun0SUN Jie1CHEN Jiuan2YAO Lu3XU Ye4XIE Yuntao5ZHANG Juan6Familial & Hereditary Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, ChinaFamilial & Hereditary Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, ChinaFamilial & Hereditary Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, ChinaFamilial & Hereditary Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, ChinaFamilial & Hereditary Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, ChinaFamilial & Hereditary Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, ChinaFamilial & Hereditary Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, ChinaObjective To compare the clinicopathological characteristics between primary and contralateral cancers in patients with metachronous bilateral breast cancer (MBBC) who carried a BRCA1/2 germline pathogenic variant. Methods A total of 496 BRCA1/2 carriers with primary unilateral breast cancer were included (196 with BRCA1 and 300 with BRCA2). Clinicopathological information of patients was collected, and the median follow-up for the entire cohort was 10.4 years (0.4-20.8 years). Results Among all patients, 31 (15.8%) of the 196 BRCA1 carriers and 49 (16.3%) of the 300 BRCA2 carriers had MBBC, respectively. Among the 31 BRCA1 carriers who developed MBBC, the proportion of triple-negative breast cancer (TNBC) in primary cancer and contralateral cancer was 61.3% and 67.7%, respectively. If the primary cancer of BRCA1-mutated MBBC was TNBC, the probability of the contralateral breast cancer with TNBC was 89.5% (17/19), which was significantly higher than that if the primary cancer was non-TNBC (33.3%, 4/12) (P=0.004). Among the 49 BRCA2 carriers who developed MBBC, the predominant molecular phenotype of the primary and contralateral cancers was HR+ & HER2- (77.6% and 67.3%, respectively; P=0.53). Conclusion Approximately 60% of BRCA1 carriers exhibit TNBC. If a BRCA1 carrier with a TNBC primary breast cancer had an MBBC, the probability of the contralateral breast cancer being TNBC phenotype is almost 89.5%.http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.23.0211brca statusmetachronous bilateral breast cancermolecular subtypetriple-negative breast cancer |
| spellingShingle | DING Xinyun SUN Jie CHEN Jiuan YAO Lu XU Ye XIE Yuntao ZHANG Juan Comparison of Clinicopathological Characteristics Between Primary and Contralateral Cancers in BRCA1/2 Carriers with Metachronous Bilateral Breast Cancers Zhongliu Fangzhi Yanjiu brca status metachronous bilateral breast cancer molecular subtype triple-negative breast cancer |
| title | Comparison of Clinicopathological Characteristics Between Primary and Contralateral Cancers in BRCA1/2 Carriers with Metachronous Bilateral Breast Cancers |
| title_full | Comparison of Clinicopathological Characteristics Between Primary and Contralateral Cancers in BRCA1/2 Carriers with Metachronous Bilateral Breast Cancers |
| title_fullStr | Comparison of Clinicopathological Characteristics Between Primary and Contralateral Cancers in BRCA1/2 Carriers with Metachronous Bilateral Breast Cancers |
| title_full_unstemmed | Comparison of Clinicopathological Characteristics Between Primary and Contralateral Cancers in BRCA1/2 Carriers with Metachronous Bilateral Breast Cancers |
| title_short | Comparison of Clinicopathological Characteristics Between Primary and Contralateral Cancers in BRCA1/2 Carriers with Metachronous Bilateral Breast Cancers |
| title_sort | comparison of clinicopathological characteristics between primary and contralateral cancers in brca1 2 carriers with metachronous bilateral breast cancers |
| topic | brca status metachronous bilateral breast cancer molecular subtype triple-negative breast cancer |
| url | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.23.0211 |
| work_keys_str_mv | AT dingxinyun comparisonofclinicopathologicalcharacteristicsbetweenprimaryandcontralateralcancersinbrca12carrierswithmetachronousbilateralbreastcancers AT sunjie comparisonofclinicopathologicalcharacteristicsbetweenprimaryandcontralateralcancersinbrca12carrierswithmetachronousbilateralbreastcancers AT chenjiuan comparisonofclinicopathologicalcharacteristicsbetweenprimaryandcontralateralcancersinbrca12carrierswithmetachronousbilateralbreastcancers AT yaolu comparisonofclinicopathologicalcharacteristicsbetweenprimaryandcontralateralcancersinbrca12carrierswithmetachronousbilateralbreastcancers AT xuye comparisonofclinicopathologicalcharacteristicsbetweenprimaryandcontralateralcancersinbrca12carrierswithmetachronousbilateralbreastcancers AT xieyuntao comparisonofclinicopathologicalcharacteristicsbetweenprimaryandcontralateralcancersinbrca12carrierswithmetachronousbilateralbreastcancers AT zhangjuan comparisonofclinicopathologicalcharacteristicsbetweenprimaryandcontralateralcancersinbrca12carrierswithmetachronousbilateralbreastcancers |